Brief: Athira Pharma Q2 EPS USD -0.18

LeonaBio

07/08/2025 21:05

Overview

Athira Q2 net loss narrows to about $7 mln from about $27 mln yr/yr

Operating expenses fall to $7.3 mln from $28 mln yr/yr

Co exploring strategic alternatives

Outlook

Athira exploring strategic alternatives to maximize stockholder value

Company plans future clinical trial for ATH-1105 in ALS

Athira pauses fosgonimeton development, focuses on ATH-1105

Result Drivers

ATH-1105 DEVELOPMENT - Positive Phase 1 trial results for ATH-1105 in ALS support continued development

R&D EXPENSES - Significant reduction in R&D expenses to $3.7 mln from $22.2 mln yr/yr

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.18
Q2 Net Income
-$6.97 mln
Q2 Operating Expenses
$7.29 mln
Q2 Operating Income
-$7.29 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Athira Pharma Inc is $0.40, about 5.3% above its August 6 closing price of $0.38

Press Release: ID:nGNX5Vq3Yf

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)